243 related articles for article (PubMed ID: 11781068)
1. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
Sami N; Bhol KC; Razzaque Ahmed A
Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
3. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
4. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
6. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.
Foster CS; Ahmed AR
Ophthalmology; 1999 Nov; 106(11):2136-43. PubMed ID: 10571350
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy.
Kumari S; Bhol KC; Rehman F; Foster CS; Ahmed AR
Cytokine; 2001 May; 14(4):218-24. PubMed ID: 11448121
[TBL] [Abstract][Full Text] [Related]
12. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
Ahmed AR
Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin treatment in laryngeal pemphigoid.
Gürcan HM; Ahmed AR
Clin Exp Dermatol; 2009 Dec; 34(8):884-6. PubMed ID: 19094130
[TBL] [Abstract][Full Text] [Related]
14. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
15. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients.
Canizares MJ; Smith DI; Conners MS; Maverick KJ; Heffernan MP
Arch Dermatol; 2006 Nov; 142(11):1457-61. PubMed ID: 17116836
[TBL] [Abstract][Full Text] [Related]
18. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
[TBL] [Abstract][Full Text] [Related]
19. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
20. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study.
Letko E; Bhol K; Foster SC; Ahmed RA
Curr Eye Res; 2000 Aug; 21(2):646-54. PubMed ID: 11148601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
